Jatenzo (Testosterone Undecanoate) Patent Expiration, LOE Window & CMS Spending

Jatenzo (Testosterone Undecanoate) by Tolmar: FDA Orange Book core substance LOE 2030-04-12 (last listed 2039-04-12), 0 AB generics, $10.1M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTolmar
FDA Application & PathwayN206089 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2030-04-12
Last Listed Patent or Exclusivity Date2039-04-12
Orange Book Patents (*PED Extensions)11 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$10.1M
2024 Medicare Part D Spend$7.9M
2024 Medicaid Spend$2.2M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel